Background: Nitric oxide helps maintain vascular function and is generated through the oxidation of arginine. Whether altered arginine metabolism may lead to elevated levels of inflammation in HIV is unclear.
Introduction
Adults with HIV remain at higher risk of cardiovascular comorbidities despite successful virologic control with antiretroviral therapy (ART) [1] [2] [3] [4] . Chronic inflammation has been shown to play a key role in cardiovascular disease (CVD) in HIV infection [5] and to remain elevated after ART initiation [6] . In addition, endothelial dysfunction has been reported in HIV, and it is known in HIV-uninfected populations to precede the development of atherosclerosis [7] .
Nitric oxide helps maintain normal vascular function through its antiatherogenic and vasodilatory effects. Nitric oxide is generated through the oxidation of arginine by endothelial nitric oxide synthase (NOS) [8] . Asymmetric dimethylarginine (ADMA) resembles arginine and can inhibit nitric oxide synthase and has subsequently been recognized as a marker of endothelial dysfunction [9] Arginine is the common substrate for both nitric oxide synthases and arginases and the global arginine bioavailability ratio accounts for levels of the substrate (arginine) and its major catabolic products (ornithine and citrulline). The global arginine bioavailability ratio (GABR) has been shown to be a better predictor of CVD risk than arginine levels alone in HIV-uninfected populations [10] ; however, it has never been assessed in HIV infection.
We hypothesize that HIV-infected participants on suppressive ART will have increased levels of ADMA, and a decrease in GABR, which will be associated with a heightened state of inflammation and immune activation when compared with HIV-uninfected individuals.
Methods

Study design
This is an observational cohort of HIV-infected and uninfected participants prospectively enrolled at University Hospitals Case Medical Center, Cleveland, Ohio. The study was approved by the local Institutional Review Board, and written informed consent was provided by all participants. All participants were at least 18 years of age, with HIV-1 infection on stable ART for at least 3 months with cumulative ART duration of at least 6 months, HIV-1 RNA less than 50 copies/ml in the last 4 months prior to study entry, not pregnant or lactating, or had an active infectious or inflammatory condition. Uncontrolled diabetes and known CVDs were excluded, similarly study participants consuming arginine supplements were excluded.
Study evaluations
Blood draws were obtained for measurements of renal and lipid profiles, glucose and insulin levels. Blood was drawn after a 12-h fast. Additionally, blood was processed and plasma and serum were cryopreserved for measurement of markers of monocyte activation, systemic, inflammation, and coagulation as previously described [11, 12] . The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated. 
Arginine biomarkers
Measurement of arginine, ornithine, citrulline, ADMA, symmetrical dimethyl arginine (SDMA), and monomethylarginine was performed by stable isotope dilution HPLC with online tandem mass spectrometry. Four volumes of methanol containing 13C6-Arg, d6-Orn, d4-Cit, d7-ADMA each 10 mmol/l was added to plasma to precipitate proteins and the supernatant after centrifugation at 13000 rpm for 10 min was collected for liquid chromatography/mass spectrometry assay. A total of 10 ml of supernatant was injected onto a HPLC column. The levels of the arginine and related metabolites were quantified by liquid chromatography/electrospray ionization/tandem mass spectrometry analysis using API 365 triple quadruple mass spectrometer (Applied Biosystems, Foster, California, USA) with Ionics EP 10þ upgrade (Concord, Ontario, California, USA) and Cohesive Technologies Aria LX Series HPLC multiplexing system (Franklin, Massachusetts, USA). Amino acids were separated with a 250 Â 4.6 mm Rexchrom S5-100-P phenyl column (Product number 728207 Regis Chemical, Morton Grove, Illinois, USA) with a 1 Â 15 mm 2 Optimize technologies Opti-Guard Phenyl guard column (optimize Technologies, Oregon City, Oregon, USA). Formic acid (0.1%) and ammonium formate (10 mmol/l) in water (solvent A) and formic acid (0.1%) and ammonium formate (10 mmol/l) in methanol (solvent B) were used as solvents. The gradient consisted of: 100% solvent A at 800 ml/min held for 0.5 min after injection, linear gradient run to 50% solvent B (50% solvent A) over 3 min, held at 50% B for 3.5 min at a flow rate of 800 ml/min, flow rate increased to 1000 ml/min with solvent composition changed to 100% B in linear fashion over 1 min, linear gradient run to 100% A at 1000 ml/min over 0.5 min, held at this composition and flow rate for 6 min. Overall, the 8.5-min data window was started at 3.5 min after injection, and mass spectrometric analyses was performed using electrospray ionization tandem mass spectrometry in the positive ion mode with multiple reaction monitoring. Intra and interassay coefficients of variance less than 10%. GABR was defined as arginine/(ornithine þ citrulline).
Statistical analysis
The primary objective of this analysis was to determine the extent to which arginine biomarkers were different between HIV-infected and uninfected participants.
Continuous variables such as age and BMI were compared using the t-test. Skewed continuous variables were transformed to zero-skewness distribution by using Box-Cox transformation. The categorical variables were compared using the x 2 test. Spearman rank correlations quantified associations between arginine biomarkers and inflammatory markers with 10% significance level. For the mean differences in biomarkers for the two groups was compared using propensity score matching method. We used a logistic regression model to predict each study participant's propensity score using covariates age, sex, race, BMI, smoking status, family history of myocardial infarction (MI), high-density lipids (HDLs), and low-density lipids (LDLs) cholesterol.
We performed separate pairwise correlation analyses for the HIV-infected and uninfected participants of inflammatory and arginine biomarkers and considered significance level of 0.10. With the significantly correlated pairs, we performed unadjusted regression analyses of inflammatory markers for HIV-infected group. Afterwards, we performed adjusted regression analyses of inflammatory markers on arginine biomarkers based on significant correlation. Variables adjusted for included age, sex, race, BMI, smoking status, family history of MI, HDLs, and LDLs cholesterol and HIV status. Stata 14 (College Station, Texas, USA) was used to perform this analysis.
Results
Baseline characteristics
Overall, 131 participant (93 HIV infected and 38 controls) were included in the analysis. Demographic information and baseline characteristics are displayed in Table 1 .
Among the arginine biomarkers, lysine, arginine, citrulline, and GABR were significantly higher (P 0.02) and SDMA was significantly lower in the HIV-infected participants (P ¼ 0.01) versus uninfected controls. D-dimer was higher in the HIV-infected participants (P < 0.01).
Association between arginine biomarkers and inflammatory markers
In HIV-infected participants, after adjusting for the CVD risk factors age, sex, race, BMI, smoking, family history of MI, HDL, and LDL, several arginine biomarkers were negatively associated with markers of inflammation, whereas ADMA and its byproduct SDMA were positively associated with markers of inflammation ( Table 2 ). In HIV-uninfected participants, GABR was negatively associated with TNFR1, D-dimer, and soluble CD163 (P 0.01) and lysine with D-Dimer (P ¼ 0.03).
Discussion
In this study, we found that HIV-infected individuals who are virologically suppressed and on stable ART do not have decreased arginine availability when compared with HIV-uninfected individuals and have similar levels of the endogenous NOS inhibitor ADMA. In addition, we found that the relationship between markers in the arginine pathway and markers of inflammation, coagulation, endothelial activation, and immune activation was more consistent in HIV-infected individuals compared with uninfected controls.
Little is known about ADMA in HIV and nothing is known about GABR. Contrary to our findings, ADMA has been found to be higher in HIV-infected patients versus controls in separate reports [13, 14] . The difference in mean ADMA reported between HIV-infected and HIV uninfected individuals has ranged between 0.03 and 0.18 mmol/l [13] [14] [15] . Mean levels of ADMA in HIV-infected individuals in our study were similar to what was found in previous reports of HIV-infected individuals who were ARTnaive and were younger than our patients [14, 16] ; however, levels in HIV-uninfected individuals were 0.18 mmol/l higher in our study than what has been reported [4, 14] . We hypothesize that our findings could be the result of several factors inherent to the demographics of our participants. First, the HIVinfected participants in our study may have had elevated ADMA levels pre-ART but, with viral suppression, these levels may have been reduced to levels comparable with those measured in the uninfected age-matched participants. This hypothesis is supported by studies that have shown that ADMA decrease after ART initiation [16, 17] . Second, ADMA levels were higher in our uninfected controls than what has previously been reported in other HIV-uninfected cohorts. The mean plasma ADMA concentrations in the Framingham Offspring Cohort study, in participants who were free of clinical CVD, was 0.53 AE 0.12 mmol/l [18] . This might be because our participants were older and ADMA is known to increase with age [19] . Finally, 55% of the HIVuninfected controls were women with a mean age of 51 years, and women have been shown to have higher ADMA levels with onset of menopause [19] .
The GABR accounts for arginine and its catabolic products (ornithine and citrulline) and has been shown to be a better predictor of CVD in HIV-uninfected patients than arginine levels alone [12] , where lower GABR was associated with higher prevalence of atherosclerotic disease and increased risk of cardiac events. We report, for the first time in HIV infection, a higher GABR compared with uninfected participants and a significant inverse association between GABR and several markers of inflammation and endothelial activation markers, including TNFRI and II, D-dimer, and soluble vascular cell adhesion molecule. This finding of consistent associations between arginine and inflammatory markers in HIV-infected individuals, but not in uninfected controls, highlights a possible role of arginine in ongoing inflammation and enhanced endothelial activation among HIV-infected individuals, even those receiving ART.
536
AIDS 2017, Vol 31 No 4 There are limitations to this study. First, there are baseline differences between the groups, including differences in sex and race, which are known to be associated with differences in arginine biomarkers and CVD risk. We adjusted for these imbalances in our analyses. The secondary objective of this study was to evaluate variables, in particular arginine biomarkers and markers of inflammation, that may account for increased risk of CVD; however, to control for the differences between the groups, all of our analyses adjusted for demographic factors that are known CVD risk factors, such as age, sex, race, BMI, smoking, family history of MI, HDL, and LDL. The small sample size and the cross-sectional design are other limitations and as such we cannot attribute cause to effect.
To our knowledge, this is the first study specifically designed to investigate the relationships among a comprehensive state-of-the art evaluation of the arginine pathway, including global arginine bioavailability ratio, and inflammation, coagulation, and endothelial activation biomarkers in HIV-infected adults receiving ART. Our findings suggest a potential mechanism for the increased inflammation in this population and, as such, the arginine pathway could be used as a novel way to target the heightened inflammation state typically measured in HIV infection. Larger longitudinal studies are needed to further define and confirm this relationship.
